-
FDA Approves Imlunestrant (Inluriyo) for Certain Hormone Receptor-Positive Breast Cancers
Imlunestrant is a hormonal therapy medicine used to treat advanced-stage hormone receptor-positive breast cancer that grew during treatment with other hormonal therapy medicines. Read our breaking news article.
-
New Hormonal Therapy Vepdegestrant Promising for Some Metastatic HR+ Breast Cancers
New Hormonal Therapy Vepdegestrant Promising for Some Metastatic HR+ Breast Cancers May 30, 2025 The new medicine offered more benefits than Faslodex. Read more…
-
Testing for ESR1 Mutations, Then Switching to Camizestrant Improves Outcomes for HR+ HER2- MBC
Testing for ESR1 Mutations, Then Switching to Camizestrant Improves Outcomes for Metastatic HR+ HER2- Breast Cancer May 31, 2025 After two years of follow-up, the new treatment improved survival and quality of life. Read more…
-
Waiting for Surgery
Hello, I'm 48 and I was recently diagnosed with Invasive Lobular cancer of my left breast after a long journey. It started in December of 2023 when on a MRI they saw a spot that they wanted to recheck in six months. I was not super concerned as this had happened before on the right-hand side and it turned out to be…
-
FDA Approves Dato-DXd for advanced-stage HR+, HER2- breast cancer
https://www.breastcancer.org/treatment/targeted-therapy/dato-dxd
-
DCIS removed but... gene mutations... now what and family thinks I should be happy
Diagnosed with DCIS (ER+/PR+) in Sept. Had it removed in Oct. Doc talked abt possible radiation and/or hormones even though I'm one of the "lucky" ones- HA! Now I'm positive for CHEK2 and RAD51C w a family history of ovarian and colon cancer (1 + 1). Waiting to hear back from gyn to screen for ovarian cx and sons need to…
-
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer Dec 12, 2024 Dr. Aditya Bardia discusses Enhertu for metastatic hormone receptor-positive, HER2-low and -ultralow breast cancer and explains those terms. At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program…
-
Surgical Options
I was just diagnosed and am deciding between treatment options. I am already scheduled for surgery but now I am having doubts about the Lumpectomy and subsequent radiation therapy. In my honest opinion, I now feel that the mastectomy could be the better choice due to avoiding the radiotherapy and hormone therapy. Feeling…
-
Can Certain Younger Post-Menopausal Women With Low-Risk Breast Cancer Skip Radiation?
Can Certain Younger Post-Menopausal Women With Low-Risk Breast Cancer Skip Radiation? Dec 6, 2023 Research suggests that some younger post-menopausal women may be able to skip radiation after lumpectomy, but there are important points to consider. Read more…
-
ART Doesn’t Increase Hormone Receptor-Positive Breast Cancer Recurrence Risk
ART Doesn’t Increase Hormone Receptor-Positive Breast Cancer Recurrence Risk Dec 7, 2023 Dr. Hatem Azim explains his new analysis of data from the POSITIVE trial. At the 2023 San Antonio Breast Cancer Symposium, Dr. Hatem Azim presented a new analysis of information from the POSITIVE trial, which found that younger women…
-
CHEK2 Mutations Linked to Hormone Receptor-Positive Cancer Treatment Resistance in Younger Women
https://www.breastcancer.org/research-news/chek2-mutations-treatment-resistance
-
Lower Oncotype DX Scores Seem Less Accurate for Black Women With Hormone Receptor-Positive Breast Cx
https://www.breastcancer.org/research-news/black-women-oncotype-less-accurate